These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 35565395)

  • 1. Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.
    Zhou Y; Li M; Zhou K; Brown J; Tsao T; Cen X; Husman T; Bajpai A; Dunn ZS; Yang L
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
    Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
    Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Basic Research and Clinical Development of Regenerative Immunotherapy Using iPS Cells].
    Kanie K; Kaneko S
    Gan To Kagaku Ryoho; 2023 May; 50(5):571-576. PubMed ID: 37218314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
    Zhu H; Kaufman DS
    Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IPSC-derived CAR-NK cells for cancer immunotherapy.
    Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
    Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
    Lahimchi MR; Maroufi F; Maali A
    Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.
    Tsiverioti CA; Gottschlich A; Trefny M; Theurich S; Anders HJ; Kroiss M; Kobold S
    Biol Chem; 2024 Jul; 405(7-8):485-515. PubMed ID: 38766710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing cell-based cancer immunotherapy through stem cell engineering.
    Li YR; Dunn ZS; Yu Y; Li M; Wang P; Yang L
    Cell Stem Cell; 2023 May; 30(5):592-610. PubMed ID: 36948187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
    Mehra V; Chhetri JB; Ali S; Roddie C
    Biology (Basel); 2023 Nov; 12(11):. PubMed ID: 37998018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy.
    Aoki T; Motohashi S; Koseki H
    Inflamm Regen; 2023 May; 43(1):27. PubMed ID: 37170375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies.
    Li YR; Dunn ZS; Zhou Y; Lee D; Yang L
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better by design: What to expect from novel CAR-engineered cell therapies?
    Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
    Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
    Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
    Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy.
    Xue D; Lu S; Zhang H; Zhang L; Dai Z; Kaufman DS; Zhang J
    Trends Biotechnol; 2023 Jul; 41(7):907-922. PubMed ID: 36858941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.
    Netsrithong R; Wattanapanitch M
    Front Immunol; 2021; 12():759558. PubMed ID: 34650571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
    Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
    Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.